Information Provided By:
Fly News Breaks for January 3, 2019
TMO, BIO
Jan 3, 2019 | 06:57 EDT
Barclays analyst Jack Meehan upgraded Bio-Rad Labratories to Overweight from Equal Weight while designating Thermo Fisher (TMO) as his Top Pick in U.S. Life Science Tools & Diagnostics for 2019. The analyst keeps a $315 price target on the former and raised his price target on the latter to $280 from $275. Looking into 2019, Life Science Tools & Diagnostics should continue to be a relative safe haven in healthcare, Meehan tells investors in a research note.
News For BIO;TMO From the Last 2 Days
There are no results for your query BIO;TMO